These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 33773271)

  • 21. Neuronal and glial CSF biomarkers in multiple sclerosis: a systematic review and meta-analysis.
    Momtazmanesh S; Shobeiri P; Saghazadeh A; Teunissen CE; Burman J; Szalardy L; Klivenyi P; Bartos A; Fernandes A; Rezaei N
    Rev Neurosci; 2021 Aug; 32(6):573-595. PubMed ID: 33594840
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neurofilament and glial fibrillary acidic protein in multiple sclerosis.
    Norgren N; Sundström P; Svenningsson A; Rosengren L; Stigbrand T; Gunnarsson M
    Neurology; 2004 Nov; 63(9):1586-90. PubMed ID: 15534240
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis.
    Fox RJ; Raska P; Barro C; Karafa M; Konig V; Bermel RA; Chase M; Coffey CS; Goodman AD; Klawiter EC; Naismith RT; Kuhle J
    Mult Scler; 2021 Nov; 27(13):2014-2022. PubMed ID: 33635141
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of delayed-release dimethyl fumarate (DMF) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies.
    Kita M; Fox RJ; Gold R; Giovannoni G; Phillips JT; Sarda SP; Kong J; Viglietta V; Sheikh SI; Okwuokenye M; Kappos L
    Clin Ther; 2014 Dec; 36(12):1958-1971. PubMed ID: 25315404
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of aerobic exercise on Neurofilament light chain and glial Fibrillary acidic protein level in patients with relapsing remitting type multiple sclerosis.
    Ercan Z; Bilek F; Demir CF
    Mult Scler Relat Disord; 2021 Oct; 55():103219. PubMed ID: 34433118
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum and CSF biomarkers in asymptomatic patients during primary HIV infection: a randomized study.
    Calcagno A; Cusato J; Cinque P; Marchetti G; Bernasconi D; Trunfio M; Bruzzesi E; Rusconi S; Gabrieli A; Muscatello A; Antinori A; Ripamonti D; Gulminetti R; Antonucci M; Nozza S
    Brain; 2024 Nov; 147(11):3742-3750. PubMed ID: 39171829
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum and cerebrospinal fluid brain damage markers neurofilament light and glial fibrillary acidic protein correlate with tick-borne encephalitis disease severity-a multicentre study on Lithuanian and Swedish patients.
    Veje M; Griška V; Pakalnienė J; Mickienė A; Bremell D; Zetterberg H; Blennow K; Lindquist L; Studahl M
    Eur J Neurol; 2023 Oct; 30(10):3182-3189. PubMed ID: 37431060
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Score Based on NfL and Glial Markers May Differentiate Between Relapsing-Remitting and Progressive MS Course.
    Huss A; Otto M; Senel M; Ludolph AC; Abdelhak A; Tumani H
    Front Neurol; 2020; 11():608. PubMed ID: 32765393
    [No Abstract]   [Full Text] [Related]  

  • 29. Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study.
    Lanzillo R; Moccia M; Palladino R; Signoriello E; Carotenuto A; Maniscalco GT; Saccà F; Bonavita S; Russo CV; Iodice R; Petruzzo M; Sinisi L; De Angelis M; Lavorgna L; De Rosa A; Romano F; Orlando V; Ronga B; Florio C; Lus G; Brescia Morra V
    Mult Scler Relat Disord; 2020 Feb; 38():101871. PubMed ID: 31786463
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased CX3CL1 in cerebrospinal fluid and ictal serum t-tau elevations in migraine: results from a cross-sectional exploratory case-control study.
    Süße M; Kloetzer C; Strauß S; Ruhnau J; Overeem LH; Bendig M; Schulze J; Reuter U; Vogelgesang A; Fleischmann R
    J Headache Pain; 2024 Apr; 25(1):46. PubMed ID: 38561692
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum glial fibrillary acidic protein and disability progression in progressive multiple sclerosis.
    Abdelhak A; Antweiler K; Kowarik MC; Senel M; Havla J; Zettl UK; Kleiter I; Skripuletz T; Haarmann A; Stahmann A; Huss A; Gingele S; Krumbholz M; Benkert P; Kuhle J; Friede T; Ludolph AC; Ziemann U; Kümpfel T; Tumani H
    Ann Clin Transl Neurol; 2024 Feb; 11(2):477-485. PubMed ID: 38111972
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of cerebrospinal fluid ubiquitin C-terminal hydrolase-L1, glial fibrillary acidic protein, and neurofilament light protein as novel markers for the diagnosis of neurosyphilis among HIV-negative patients.
    Chen R; Lin LR; Xiao Y; Ke WJ; Yang TC
    Int J Infect Dis; 2023 Feb; 127():36-44. PubMed ID: 36400375
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tau, Glial Fibrillary Acidic Protein, and Neurofilament Light Chain as Brain Protein Biomarkers in Cerebrospinal Fluid and Blood for Diagnosis of Neurobiological Diseases.
    Park Y; Kc N; Paneque A; Cole PD
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928000
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum Ubiquitin C-Terminal Hydrolase-L1, Glial Fibrillary Acidic Protein, and Neurofilament Light Chain Are Good Entry Points and Biomarker Candidates for Neurosyphilis Diagnosis Among Patients Without Human Immunodeficiency Virus to Avoid Lumbar Puncture.
    Xie L; Li W; Ye WM; Xiao Y; Ke WJ; Niu JJ; Yang TC
    Clin Infect Dis; 2023 Aug; 77(3):472-479. PubMed ID: 36929815
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relevance of dedicated multiple sclerosis serum biomarkers in predicting contrast enhancement with gadolinium: Results from the REDUCE-GAD trial.
    Schaefer JH; Schaller-Paule MA; Wenger K; Mayer C; Mann U; Bickert A; Steffen F; Bittner S; Yalachkov Y; Foerch C
    Eur J Neurol; 2023 Aug; 30(8):2393-2400. PubMed ID: 37183506
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum assessment of traumatic axonal injury: the correlation of GFAP, t-Tau, UCH-L1, and NfL levels with diffusion tensor imaging metrics and its prognosis utility.
    Castaño-Leon AM; Sánchez Carabias C; Hilario A; Ramos A; Navarro-Main B; Paredes I; Munarriz PM; Panero I; Eiriz Fernández C; García-Pérez D; Moreno-Gomez LM; Esteban-Sinovas O; Garcia Posadas G; Gomez PA; Lagares A
    J Neurosurg; 2023 Feb; 138(2):454-464. PubMed ID: 35901687
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined Cerebrospinal Fluid Neurofilament Light Chain Protein and Chitinase-3 Like-1 Levels in Defining Disease Course and Prognosis in Multiple Sclerosis.
    Gil-Perotin S; Castillo-Villalba J; Cubas-Nuñez L; Gasque R; Hervas D; Gomez-Mateu J; Alcala C; Perez-Miralles F; Gascon F; Dominguez JA; Casanova B
    Front Neurol; 2019; 10():1008. PubMed ID: 31608004
    [No Abstract]   [Full Text] [Related]  

  • 38. Assessing tissue damage in multiple sclerosis: a biomarker approach.
    Burman J; Zetterberg H; Fransson M; Loskog AS; Raininko R; Fagius J
    Acta Neurol Scand; 2014 Aug; 130(2):81-9. PubMed ID: 24571714
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis.
    Axelsson M; Malmeström C; Gunnarsson M; Zetterberg H; Sundström P; Lycke J; Svenningsson A
    Mult Scler; 2014 Jan; 20(1):43-50. PubMed ID: 23702432
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cerebrospinal fluid levels of GFAP and pNF-H are elevated in patients with chronic spinal cord injury and neurological deterioration.
    Holmström U; Tsitsopoulos PP; Holtz A; Salci K; Shaw G; Mondello S; Marklund N
    Acta Neurochir (Wien); 2020 Sep; 162(9):2075-2086. PubMed ID: 32588294
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.